Yeeun Shim

Yeeun Shim

Auto-generated profile, based on publicly available information

Yeeun Shim

Department of Laboratory Medicine, Graduate School of Medical Sciences, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YKYoo-Na Kim
Yoo-Na Kim
YSYeeun Shim
Yeeun Shim
JSJieun Seo
Jieun Seo
ZCZisun Choi
Zisun Choi
YLYong Jae Lee
Yong Jae Lee
SLSeung-Tae Lee
Seung-Tae Lee
Purpose: Patient-specific molecular alterations leading to PARP inhibitor (PARPi) resistance are relatively unexplored. In this study, we analyzed serially collected circulating tumor DNA (ctDNA) from patients with BRCA1/2 mutations who received PARPis to investigate the resistance mechanisms and their significance in postprogression treatment response and survival. Experimental Design: Patients were prospectively enrolled between January 2018 and December 2021 (NCT05458973). Whole-blood samples were obtained before PARPi administration and serially every 3 months until progression. ctDNA was extracted from the samples and sequenced with a 531-gene panel; gene sets for each resistance mechanism were curated. Results: Fifty-four patients were included in this analysis. Mutation profiles of genes in pre-PARPi samples indicating a high tumor mutational burden and alterations in genes associated with replication fork stabilization and drug efflux were associated with poor progression-free survival on PARPis. BRCA hypomorphism and reversion were found in 1 and 3 patients, respectively. Among 29 patients with matched samples, mutational heterogeneity increased postprogression on PARPis, showing at least one postspecific mutation in 89.7% of the patients. These mutations indicate non-exclusive acquired resistance mechanisms—homologous recombination repair restoration (28%), replication fork stability (34%), upregulated survival pathway (41%), target loss (10%), and drug efflux (3%). We observed poor progression-free survival with subsequent chemotherapy in patients with homologous recombination repair restoration (P = 0.003) and those with the simultaneous involvement of two or more resistance mechanisms (P = 0.040). Conclusions: Analysis of serial ctDNAs highlighted multiple acquired resistance mechanisms, providing valuable insights for improving postprogression treatment and survival.

3 October 2022 in Clinical Genetics
Verified
Journal Article
Closed access
HKHongkyung Kim
Hongkyung Kim
YSYeeun Shim
Yeeun Shim
TLTaek Gyu Lee
Taek Gyu Lee
DWDongju Won
Dongju Won
JCJong Rak CHOI
Jong Rak CHOI
SLSeung-Tae Lee
Seung-Tae Lee

11 January 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
MKMinkwan Kim
Minkwan Kim
JKJin Ju Kim
Jin Ju Kim
SLSeung-Tae Lee
Seung-Tae Lee
YSYeeun Shim
Yeeun Shim
HLHyeonah Lee
Hyeonah Lee
IJIn Hyun Jung
In Hyun Jung
Minkwan Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Yeeun Shim, M.S., Hyeonah Lee, Ph.D., SungA Bae, M.D., Ph.D., Nak-Hoon Son, Ph.D., Saeam Shin, M.D., Ph.D., and In Hyun Jung, M.D., Ph.D.. Ann Lab Med 2024;44:279-88. https://doi.org/10.3343/alm.2023.0268

4 March 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YSYeeun Shim
Yeeun Shim
YKYu-Kyung Koo
Yu-Kyung Koo
SSSaeam Shin
Saeam Shin
SLSeung-Tae Lee
Seung-Tae Lee
KLKyung-A Lee
Kyung-A Lee
JCJong Rak CHOI
Jong Rak CHOI
Yeeun Shim, M.S., Yu-Kyung Koo, M.D., Saeam Shin, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Kyung-A Lee, M.D., Ph.D., and Jong Rak Choi, M.D., Ph.D.. Ann Lab Med 2024;44:324-34. https://doi.org/10.3343/alm.2023.0339

10 May 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
YSYeeun Shim
Yeeun Shim
JSJieun Seo
Jieun Seo
SLSeung-Tae Lee
Seung-Tae Lee
JCJong Rak CHOI
Jong Rak CHOI
YCYoung-Chul Choi
Young-Chul Choi
HPHyung Jun Park
Hyung Jun Park
Yeeun Shim, M.S., Jieun Seo, Ph.D., Seung-Tae Lee, M.D., Ph.D., Jong Rak Choi, M.D., Ph.D., Young-Chul Choi, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Hyung Jun Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2023.0437

25 November 2025
Verified
Other
Open access
YKYoo-Na Kim
Yoo-Na Kim
YSYeeun Shim
Yeeun Shim
JSJieun Seo
Jieun Seo
ZCZisun Choi
Zisun Choi
YLYong Jae Lee
Yong Jae Lee
SLSeung-Tae Lee
Seung-Tae Lee
Purpose:Patient-specific molecular alterations leading to PARP inhibitor (PARPi) resistance are relatively unexplored. In this study, we analyzed serially collected circulating tumor DNA (ctDNA) from patients with BRCA1/2 mutations who received PARPis to investigate the resistance mechanisms and their significance in postprogression treatment response and survival.Experimental Design:Patients were prospectively enrolled between January 2018 and December 2021 (NCT05458973). Whole-blood samples were obtained before PARPi administration and serially every 3 months until progression. ctDNA was extracted from the samples and sequenced with a 531-gene panel; gene sets for each resistance mechanism were curated.Results:Fifty-four patients were included in this analysis. Mutation profiles of genes in pre-PARPi samples indicating a high tumor mutational burden and alterations in genes associated with replication fork stabilization and drug efflux were associated with poor progression-free survival on PARPis. BRCA hypomorphism and reversion were found in 1 and 3 patients, respectively. Among 29 patients with matched samples, mutational heterogeneity increased postprogression on PARPis, showing at least one postspecific mutation in 89.7% of the patients. These mutations indicate non-exclusive acquired resistance mechanisms—homologous recombination repair restoration (28%), replication fork stability (34%), upregulated survival pathway (41%), target loss (10%), and drug efflux (3%). We observed poor progression-free survival with subsequent chemotherapy in patients with homologous recombination repair restoration (P = 0.003) and those with the simultaneous involvement of two or more resistance mechanisms (P = 0.040).Conclusions:Analysis of serial ctDNAs highlighted multiple acquired resistance mechanisms, providing valuable insights for improving postprogression treatment and survival.